Response redefined with the power of lenvatinib in first-line unresectable HCC therapy
22 Aug 2024
byDr. David Tai; Dr. Yong Wei Peng; Lee Chin Peng, MBBS, FRCOG, FHKAM(O&G); Jan Welch, MBE, BSc, FRCP, FFFLM
Systemic therapy plays a central role in the management of unresectable hepatocellular carcinoma (HCC). In this rapidly developing therapy area, recent clinical trials are redefining systemic treatments, including multiple kinase inhibitors (MKI). During the recent Gastro Lunch and Learn sessions sponsored by Eisai, Dr David Tai and Dr Yong Wei Peng discussed the evidence behind MKIs such as lenvatinib (Lenvima®) in the treatment of unresectable HCC through a case-based approach.
